A competition is underway between pharmaceutical companies, including Eli Lilly and Novo Nordisk, to develop and market obesity drugs. Novo Nordisk has sued Eli Lilly, alleging misleading advertisements, as the two companies vie for position in the weight-loss drug market. The outcome of this competition is uncertain, with some reports suggesting Novo Nordisk's product is currently leading, while others consider Eli Lilly's prospects.